Related Experiment Videos

[Neonatal systemic candidiasis]

Presse Medicale (Paris, France : 1983)
|May 30, 1987
PubMed

Insights

Systemic Candida infections in premature infants are linked to immature immunity, catheters, and antibiotics. 5-fluorocytosine is recommended as the primary treatment for these serious fungal infections.

Area of Science:

  • Neonatal Medicine
  • Mycology
  • Infectious Diseases

Context:

  • Premature infants (<33 weeks gestation, <1500g) are susceptible to systemic Candida infections.
  • Factors contributing include immature cellular immunity, prolonged intravascular catheter use, and broad-spectrum antibiotic administration.
  • Candida bloodstream infections present with non-specific septicemia signs.

Purpose:

  • To evaluate the efficacy of 5-fluorocytosine in treating systemic Candida infections in premature neonates.
  • To establish a recommended first-line treatment protocol for neonatal candidiasis.

Summary:

  • Six premature infants with Candida bloodstream infections were treated.
  • Five infants received 5-fluorocytosine, achieving cure.
  • One infant required amphotericin B treatment.

Impact:

  • 5-fluorocytosine is proposed as the preferred first-choice treatment for systemic candidiasis in premature babies.
  • A policy for Candida eradication in neonatology units is advocated.
  • This study informs clinical practice and infection control strategies in neonatal intensive care settings.

Related Concept Videos